Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Sumanta Kumar Pal

Showing results (51-60 of 94) with videos related to

Pageof 10
Sort By:
European Urology|March 14, 2015
Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and AmplificationNorma Palma, John C Morris, Siraj M Ali, et al.
European Urology|February 27, 2018
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United StatesSumanta Kumar Pal, Jean Hoffman-Censits, Hanzhe Zheng, et al.
Current Treatment Options in Oncology|February 22, 2018
The Role of Circulating Tumor DNA in Renal Cell CarcinomaPaulo G Bergerot, Andrew W Hahn, Cristiane Decat Bergerot, et al.
European Urology|March 23, 2015
Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 MutationSiraj M Ali, Philip J Stephens, Vincent A Miller, et al.
World Journal of Urology|October 22, 2020
COVID-19 and financial toxicity in patients with renal cell carcinomaMichael D Staehler, Dena J Battle, Cristiane D Bergerot, et al.
Molecular Cancer Therapeutics|February 22, 2012
Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigmSumanta Kumar Pal, Stephen Williams, David Y Josephson, et al.
Journal of Clinical Medicine|March 11, 2023
Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy ApproachesTanya Barauskas Dorff, Saro Kasparian, Natasha Garg, et al.
Plos One|August 27, 2015
Conditional Survival in de novo Metastatic Urothelial CarcinomaSumanta Kumar Pal, Yulan Ingrid Lin, Bertram Yuh, et al.
Psycho-Oncology|April 2, 2021
Emotional problem-related distress screening and its prevalence by cancer type: Assessment by patients' characteristics and level of assistance requestedCristiane Decat Bergerot, Marianne Razavi, Karen Lynn Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder CancerSumanta Kumar Pal, Neeraj Agarwal, Stephen Anthony Boorjian, et al.
Pageof 10

Showing results (51-60 of 94) with videos related to

Sort By:
Pageof 10
European Urology|March 14, 2015
Exceptional Response to Pazopanib in a Patient with Urothelial Carcinoma Harboring FGFR3 Activating Mutation and AmplificationNorma Palma, John C Morris, Siraj M Ali, et al.
European Urology|February 27, 2018
Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United StatesSumanta Kumar Pal, Jean Hoffman-Censits, Hanzhe Zheng, et al.
Current Treatment Options in Oncology|February 22, 2018
The Role of Circulating Tumor DNA in Renal Cell CarcinomaPaulo G Bergerot, Andrew W Hahn, Cristiane Decat Bergerot, et al.
European Urology|March 23, 2015
Selective Response to Mammalian Target of Rapamycin Inhibition in a Patient with Metastatic Renal Cell Carcinoma Bearing TSC1 MutationSiraj M Ali, Philip J Stephens, Vincent A Miller, et al.
World Journal of Urology|October 22, 2020
COVID-19 and financial toxicity in patients with renal cell carcinomaMichael D Staehler, Dena J Battle, Cristiane D Bergerot, et al.
Molecular Cancer Therapeutics|February 22, 2012
Novel therapies for metastatic renal cell carcinoma: efforts to expand beyond the VEGF/mTOR signaling paradigmSumanta Kumar Pal, Stephen Williams, David Y Josephson, et al.
Journal of Clinical Medicine|March 11, 2023
Difficulties in Defining Oligometastatic Prostate Cancer: Implications for Clinical Trial Accrual and Community Practice Adoption of Metastasis-Directed Therapy ApproachesTanya Barauskas Dorff, Saro Kasparian, Natasha Garg, et al.
Plos One|August 27, 2015
Conditional Survival in de novo Metastatic Urothelial CarcinomaSumanta Kumar Pal, Yulan Ingrid Lin, Bertram Yuh, et al.
Psycho-Oncology|April 2, 2021
Emotional problem-related distress screening and its prevalence by cancer type: Assessment by patients' characteristics and level of assistance requestedCristiane Decat Bergerot, Marianne Razavi, Karen Lynn Clark, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 27, 2016
National Comprehensive Cancer Network Recommendations on Molecular Profiling of Advanced Bladder CancerSumanta Kumar Pal, Neeraj Agarwal, Stephen Anthony Boorjian, et al.
Pageof 10